Dr. Ramya Dwivedi

Feature Writer

Ph.D. Biotechnology

Ramya has a Ph.D. in Biotechnology from the National Chemical Laboratories (CSIR-NCL), in Pune. Her work consisted of functionalizing nanoparticles with different molecules of biological interest, studying the reaction system and establishing useful applications.

She also has had exposure to research in molecular biology, immunology, evolutionary biology, chemistry, AFM imaging and analysis, and spectroscopy. Her interests cover interdisciplinary sciences.

She enjoyed teaching ‘Physics in Nanoscience and Nanotechnology’ as an Assistant Professor at SRM University. After a short period there, she pursued research further as the prestigious CSIR Nehru Science Post Doctoral Fellow in the field of Nanosciences.

Her research helped her skill for writing manuscripts, news articles, and reviews. She has also contributed as a peer reviewer for journals from RSC and ACS publications. After a maternity break and raising two daughters, Ramya is now working to get back into learning, research, and writing.

When Ramya is not immersed in a book, she loves to cook, travel and play with her daughters. She lives in Chennai. She is also a budding gardener. She strongly believes in doing her bit for the environment and in healthy living.

She has recently finished an online course: ‘Writing in the Sciences’, offered by Stanford University. Presently Ramya sees her freelance writing as a primer to her endeavors in science.

See less

Articles from Ramya

Investigation of SARS-CoV-2 antibody responses in patients with aggressive hematological malignancies

Patients with hematological malignancy (PHM), also infected with COVID-19, were investigated for SARS-CoV-2 antibody responses while undergoing systemic anti-cancer therapy. While no obvious correlation is found between the serological results and the hematological diagnosis and the treatment, the immune response is similar to the severity of COVID-19 infection observed in the general population.

4 Oct 2020

A TLR2 agonist reduces SARS-CoV-2 in upper respiratory tract of ferret model

In a recent bioRxiv* preprint paper, Professor Miles W. Carroll et al. study an agonist for reducing the SARS-CoV-2's viral load. They show that prophylactic intra-nasal administration of TLR2/6 (toll-like receptor) agonist, INNA-051, reduces viral RNA in the nose and throat, in a ferret model.

30 Sep 2020

Special formulation of inhaled niclosamide may be effective against SARS-CoV-2

Now in new research published on the preprint server bioRxix*, a novel formulation of the drug Niclosamide (NIC) is observed to be effective against SARS-CoV-2 and MERS-CoV in mouse models; it also protects against methicillin-resistance Staphylococcus aureus pneumonia and inflammatory lung damage.

28 Sep 2020

Cold plasma inactivates SARS-CoV-2

In one such effort, Zhitong Chen et al., in a recent medRxiv* preprint paper find that by employing an efficient cold atmospheric plasma (CAP) with argon feed gas on different surfaces inactivates the infectious SARS-CoV-2 virus.

24 Sep 2020

Elegant, efficient way to find recombinant SARS-CoV-2 viruses from >85,000 genomes

The low divergence of near-identical genomes that are sequenced in short periods presents a statistical challenge that is not addressed by methods available currently. In a recent bioRxiv** paper, Ales Varabyou et al. from John Hopkins University present an efficient method designed to detect recombination and reassortment events between clades of viral genomes – a new algorithm called ‘Bolotie’.

23 Sep 2020

No discernable difference in SARS-CoV-2 viral loads of young children versus older children and adults

Sharline Madera et al. , in a recent medRxiv* preprint paper, show a detailed investigation of viral nucleic acid among young children and adults, involving over 5,000 cases confirmed by RT-PCR (Reverse Transcriptase – Polymerase Chain Reaction) assay.

23 Sep 2020

COVID-19 mitigation efforts significantly decrease influenza activity

The mitigation strategies implemented to curb the spread of COVID-19 appears to reduce the transmission of influenza in the United States, Australia, Chile, and South Africa. These strategies may augment influenza vaccines, especially for high-risk populations during the seasonal influenza transmission.

21 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

LOX-1-immature neutrophils may help identify COVID-19 patients at risk of thrombosis complication

To predict severe outcome in COVID-19 patients, innate immune cellular signals are analyzed, identifying two novel neutrophil subsets: LOX-1- and CD123-expressing CD10-CD64+. Thromboembolic events correlated with high LOX-1 immature neutrophils – a potential prognostic signature.

17 Sep 2020

SARS-CoV-2 infection severity linked to superior humoral immunity against the S-protein

In a recent bioRxiv* preprint paper, Jenna J. Guthmiller et al., focus on the acute infection of SARS-CoV-2 and observe that the humoral immunity is distinctive with the infection stage and viral antigens.

16 Sep 2020